Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of stopping long-acting glucagon-like peptide-1 receptor agonists GLP-1 RAs for one week before undergoing an esophagogastroduodenoscopy EGD. The goal is to see if a one-week pause improves the quality of stomach preparation and reduces the need for repeating the EGD procedure. This is a Phase 3 randomized controlled trial designed to evaluate this specific pre-procedural recommendation. Participants are assigned to one of two groups those who continue using GLP-1 RAs without stopping, and those who stop the medication for one week before the EGD. The study compares these two approaches to determine their effects on stomach cleanliness measured during the EGD. During the study, participants will undergo EGD and their stomach preparation quality will be assessed using the PEACE scoring system. The assessment period covers from enrollment until at least 30 days after treatment. The study includes adults aged 18 to 70 years who are already using GLP-1 RAs continuously for at least four weeks or are on near-maximal doses. Researchers will monitor safety and outcomes throughout the trial, which is expected to complete in 2030.
Actively Recruiting
Researchers are studying the effects of stopping GLP-1 receptor agonists GLP-1 RAs before a colonoscopy to improve bowel preparation quality and reduce the need for repeat procedures. GLP-1 RAs are used for type 2 diabetes and other health conditions but can slow stomach emptying and gut movement, which may affect how well the bowel is cleaned before colonoscopy. This trial aims to find the best timing to stop these medications to ensure a clear colon for accurate screening and diagnosis. Participants are randomly assigned to either stop GLP-1 RAs for one week before the colonoscopy or continue as usual without stopping. The study compares these two groups to assess bowel cleansing quality using the Boston Bowel Preparation Scale BBPS. Both groups follow standard bowel preparation with split-dose polyethylene glycol, and the study observes how medication timing affects bowel cleanliness and the need for repeat colonoscopies. During the study, participants undergo bowel preparation and colonoscopy, with researchers evaluating bowel cleanliness through BBPS scores from enrollment until 30 days after the procedure. The study also monitors for incomplete bowel preparation rates and any need for repeat colonoscopies. Participants will be assessed through clinical visits and bowel preparation quality will be closely tracked to develop evidence-based guidelines for managing GLP-1 RA discontinuation before colonoscopy.